Alzheimer’s disease, the primary cause of dementia in the elderly, imposes a tremendous social and economic burden on modern society.
In Japan, the burden of the disease in 2050 is estimated to be a half a trillion US dollars, a figure equivalent to the government’s annual revenues.
Unfortunately, it has proven very difficult to develop drugs capable of ameliorating the disease. After a tremendous burst of progress in the 1990s, the pace of discoveries has slowed. Dr. Saido believes that part of the difficulty is the inadequacy of current mouse models to replicate the real conditions of Alzheimer’s disease and allow an understanding of the underlying mechanisms that lead to neurodegeneration. In fact, much of the research in Alzheimer’s disease over the past decade may be flawed, as it was based on unrealistic models.
The problem with older mouse models is that they overexpress a protein called amyloid precursor protein, or APP, which gives rise to the amyloid-beta (Abeta) peptides that accumulate in the brain, eventually leading to the neurodegeneration that characterizes Alzheimer’s disease. However, in mice the overexpression of APP gives rise to effects which are not seen in human Alzheimer’s disease.
For example, the APP mutant mice often die of unknown causes at a young age, and the group believes this may be related to the generation of toxic fragments of APP, such as CTF-beta. In addition, some of the fragments of APP could be neuroprotective, making it difficult to judge whether drugs are being effective due to their effect on Abeta peptides, which are known to be involved in human AD, or whether it is due to other effects that would not be seen in human disease. In addition, the gene for expressing APP is inserted in different places in the genome, and may knock out other genes, creating artifacts that are not seen in humans.
With this awareness, more than a decade ago Dr. Saido launched a project to develop a new mouse model that would allow more accurate evaluation of therapies for the disease. One of the major hurdles involved a part of the gene, intron 16, which they discovered was necessary for creating more specific models.
The first mice model they developed (NL-F/NL-F) was knocked in with two mutations found in human familial Alzheimer’s disease. The mice showed early accumulation of Abeta peptides, and importantly, were found to undergo cognitive dysfunction similar to the progression of AD seen in human patients. A second model, with the addition of a further mutation that had been discovered in a family in Sweden, showed even faster initiation of memory loss.
These new models could help in two major areas. The first model, which expresses high levels of the Abeta peptides, seems to realistically model the human form of AD, and could be used for elucidating the mechanism of Abeta deposition. The second model, which demonstrates AD pathology very early on, could be used to examine factors downstream of Abeta-40 and Abeta-42 deposition, such as tauopathy, which are believed to be involved in the neurodegeneration. These results may eventually contribute to drug development and to the discovery of new biomarkers for Alzheimer’s disease. The group is currently looking at several proteins, using the new models, which have potential to be biomarkers.
According to Dr. Saido, “We have a social responsibility to make Alzheimer’s disease preventable and curable. The generation of appropriate mouse models will be a major breakthrough for understanding the mechanism of the disease, which will lead to the establishment of presymptomatic diagnosis, prevention and treatment of the disease.”
The Latest on: Alzheimer’s
[google_news title=”” keyword=”Alzheimer’s” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Alzheimer’s
- New ‘Doctor Who’ Premieres, ‘Baby Reindeer’ Stars Make Red Carpet Debut and More of This Week’s Best Eventson May 10, 2024 at 10:36 pm
Executive producer Gary Goetzman, writer/director Dee Rees and stars Austin Butler, Callum Turner, Anthony Boyle, Nate Mann, Raff Law, Branden Cook and Josiah Cross reunited on Saturday for an FYC ...
- Order Of The Eastern Star WV Chapter hosts an Alzheimer’s candlelight walkon May 10, 2024 at 8:07 pm
One of the most common diseases affecting Americans is Alzheimer’s Disease with more than 5 million Americans are living with the disease. This includes about 200,000 people under the age of 65. One ...
- Ozarks nonprofit offers advice for Alzheimer’s patients for Mother’s Dayon May 10, 2024 at 7:18 pm
The Alzheimer’s Foundation of America is offering some tips for how families can honor their mothers who are living with Alzheimer’s or related dementia.
- I’m 72, worth over $2M and have no close relatives. Now ‘I worry for my future’ as mom had Alzheimer’s. What’s my move?on May 10, 2024 at 1:31 pm
I am 72 and worry about my financial future if I become confused or mentally unable to handle my affairs. My mother had Alzheimer’s for eight years and was in a nursing home, but she had me to help ...
- Lecanemab's Promise and Peril: Alzheimer's Treatment Dilemmaon May 10, 2024 at 1:15 pm
The risks and benefits of lecanemab therapy were highlighted at the recent American Geriatrics Society conference.
- Young People with Diabetes May Face Higher Alzheimer's Riskon May 10, 2024 at 12:47 am
A new study suggests that early-onset diabetes may increase the risk of Alzheimer’s disease. Controlling diabetes with lifestyle changes or medication may help lower dementia risk, experts say.
- Alzheimer's Newson May 9, 2024 at 4:59 pm
Their technique will help scientists differentiate synthetic peptides from toxic types found in Alzheimer's ... Nanomaterial That Mimics Proteins Could Be Basis for New Neurodegenerative Disease ...
- Researchers attempting to cure Alzheimer's by repurposing existing drugon May 9, 2024 at 3:46 pm
For the past three years, researchers at the Cleveland Clinic have been studying repurposing a well-known drug used for erectile dysfunction and high blood pressure.
- A gene long thought to just raise the risk for Alzheimer's may cause some caseson May 9, 2024 at 2:15 pm
More than 6 million Americans, and millions more worldwide, have Alzheimer’s. A handful of genes are known to cause rare “early-onset” forms, mutations passed through families that trigger symptoms ...
- Resources for Alzheimer's screening, treatment are woefully inadequate in Ohio | Opinionon May 9, 2024 at 6:10 am
A patient’s delay in a diagnosis is not their fault, but could be disqualifying them for available treatments.
via Bing News